1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education

1/2：UHCOP-DLDCCC 联盟：癌症药物发现/开发和教育

• 批准号: 9789209
• 负责人: Diana S-L. Chow
• 金额: $ 27.88万
• 依托单位: UNIVERSITY OF HOUSTON
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9789209
• 关键词: Address; Administrator; Advisory Committees; African American; Antineoplastic Agents; Applications Grants; Awareness; Cancer Biology; Cancer Burden; Cancer Center Planning Grant; Cancer Survivorship; Cessation of life; Chemistry; Cities; Clinical; Clinical Trials; Communities; Complement; Comprehensive Cancer Center; Core Facility; DNA; Data; Development; Diagnosis; Education; Education Projects; Education and Outreach; Educational Curriculum; Ensure; Ethnic group; Exhibits; Funding; Future; Genome; Goals; Grant; Health; Hispanic Americans; In Vitro; Incidence; Infrastructure; Institution; Joints; Lead; Libraries; Malignant Neoplasms; Medical center; Medicine; Mentors; Methylation; Mus; Patients; Peptoids; Pharmacologic Substance; Pharmacy Faculty; Pharmacy facility; Pilot Projects; Population; Population Group; Prevalence; Primary carcinoma of the liver cells; Program Development; Proteins; Records; Research; Research Personnel; Research Project Grants; Resistance; Students; Technology; Texas; Time; Training; Training and Education; Transcription Coactivator; United States; United States National Institutes of Health; Universities; anticancer research; cancer health disparity; cancer therapy; career; college; design; drug development; drug discovery; education research; experience; genome wide methylation; graduate student; health disparity; hormone therapy; in vivo evaluation; inhibitor/antagonist; innovation; lectures; malignant breast neoplasm; meetings; member; methylation pattern; multidisciplinary; new technology; novel; outreach; prognostic; programs; research and development; small molecule inhibitor; success; training opportunity; treatment trial; undergraduate research; undergraduate student

SUMMARY OF P20 APPLICATION Our University of Houston College of Pharmacy (UHCOP)-Dan L. Duncan Comprehensive Cancer Center (DLDCCC) alliance will develop the infrastructure for a joint drug discovery/development research program to treat cancers with a health disparity and a joint Cancer Research Education Program (CREP). This alliance is built on complementary expertise in cutting-edge cancer drug discovery technologies at DLDCCC/Baylor College of Medicine (BCM) and in development of cancer drugs at UHCOP. The UHCOP is a constituent of the University of Houston (UH), which is an institution serving underserved health disparity populations (ISUPS). UHCOP faculty members bring a unique perspective from an ISUPS, which is complemented by a wealth of pharmaceutical discovery and development experience, existing programs for undergraduate research, and clinical expertise in working with underserved communities. The DLDCCC, an NCI-designated Comprehensive Cancer Center, contributes prominent experience and perspective in current cancer treatments and clinical trials, cutting edge drug discovery technologies and expertise, cancer research core facilities, and existing undergraduate and graduate training and education programs, including those for patients with cancer health disparities. UHCOP and BCM are member institutions of the Texas Medical Center, the largest medical center in the world. The UHCOP/DLDCCC alliance will be led by an Administrative Core, comprised of senior and experienced investigators in drug discovery/development and cancer biology research. The Internal Advisory Committee (IAC), composed of experienced and senior cancer research and/or education experts, will guide the alliance to ensure the successful completion of the proposed goals. The Administrative Core and IAC will serve as mentors to Co-Leaders of pilot projects, the CREP, and participating early-stage investigators and underrepresented (UR) trainees. We have selected two co-developed and collaborative Pilot Projects, from a total of six, to demonstrate the feasibility of the joint infrastructure for drug discovery/development research investigating cancers with health disparities. These pilot projects have strong potential to launch bi-institutional, NIH-funded cancer drug discovery/development programs and create state-of-the-art cancer research training opportunities. We have co-developed a synergistic CREP that will encourage and prepare UR trainees to enter careers in cancer research. Through research experiences, cancer-specific curricula, and education outreach efforts to the UR trainees, the CREP will provide a platform for long-term sustained efforts for enlarging the pipeline of UR trainees in cancer research. The ultimate goal of the UHCOP-DLDCCC alliance will be to support a multiplier effect by developing joint infrastructure in drug discovery/development, education, and novel cancer technologies to target the unmet need of tackling cancer health disparities and generate preliminary data for successful subsequent NCI R-type grant funding.

P20申请摘要 我们的休斯顿大学药学院 (UHCOP)-Dan L. Duncan 综合癌症中心 （DLDCCC）联盟将为联合药物发现/开发研究计划开发基础设施，以 通过健康差异和联合癌症研究教育计划 (CREP) 治疗癌症。这个联盟是 以 DLDCCC/贝勒在尖端癌症药物发现技术方面的互补专业知识为基础 医学院 (BCM) 并在 UHCOP 开发癌症药物。 UHCOP 是 休斯顿大学 (UH) 是一所为服务不足的健康差距人群 (ISUPS) 提供服务的机构。 UHCOP 教职人员从 ISUPS 中带来了独特的视角，并辅以丰富的经验 药物发现和开发经验、现有的本科研究项目，以及 与服务不足的社区合作的临床专业知识。 DLDCCC，NCI 指定的综合性 癌症中心，在当前癌症治疗和临床方面贡献了杰出的经验和观点 试验、尖端药物发现技术和专业知识、癌症研究核心设施以及现有的 本科生和研究生培训和教育计划，包括针对癌症健康患者的培训和教育计划 差异。 UHCOP 和 BCM 是最大的医疗中心德克萨斯医学中心的成员机构 在世界上。 UHCOP/DLDCCC 联盟将由一个行政核心领导，该核心由高级和 药物发现/开发和癌症生物学研究方面经验丰富的研究人员。内部咨询 委员会（IAC）由经验丰富的资深癌症研究和/或教育专家组成，将指导 确保联盟顺利完成所提出的目标。行政核心和 IAC 将 担任试点项目联合领导者、CREP 和参与早期研究人员的导师 代表性不足的 (UR) 学员。我们从一个共同开发和协作的试点项目中选择了两个 总共六个，展示药物发现/开发研究联合基础设施的可行性 研究具有健康差异的癌症。这些试点项目具有启动双机构、 NIH 资助的癌症药物发现/开发项目并创建最先进的癌症研究培训 机会。我们共同开发了一个协同 CREP，将鼓励和准备 UR 学员进入 癌症研究的职业。通过研究经验、癌症特定课程和教育推广 CREP 将为 UR 学员的努力提供一个长期持续努力的平台，以扩大 UR 癌症研究受训人员的管道。 UHCOP-DLDCCC 联盟的最终目标是 通过在药物发现/开发、教育和药物开发方面建立联合基础设施来支持乘数效应 新颖的癌症技术，旨在解决癌症健康差异方面未得到满足的需求，并产生 成功后续 NCI R 型赠款资助的初步数据。